Tuesday - September 21, 2021
International Association for Study of Lung Cancer: Immune Checkpoint Inhibitors Convey Survival Benefit in Patients With Non-Small Cell Lung Cancer
September 14, 2021
DENVER, Colorado, Sept. 14 (TNSRes) -- The International Association for the Study of Lung Cancer issued the following news release on Sept. 13, 2021:

Because elderly patients with non-small cell lung cancer are likely to be excluded from clinical trials due to their lower functional capacity or comorbidities, survival benefit from immune checkpoint inhibitors (ICIs) remains unclear. In patients with non-small cell lung cancer (NSCLC), ICIs have become one of the standard pharmacolo . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products